Correction to Lancet Oncol 2025; 26: 629–40

Abstract

Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol 2025; 26: 629–40—In this Article, the first sentence of the fifth paragraph of the Discussion section should have read “Our translational research suggests that higher baseline expression of ERBB2, PD-1, and PD-L1, and ctDNA negativity are associated with pathological complete response after neoadjuvant pembrolizumab plus dual HER2 blockade.” This correction has been made to the online version as of Sept 29, 2025.